Dynamic features of the selective pressure on the human immunodeficiency virus type 1 (HIV-1) gp120 CD4-binding site in a group of long term non progressor (LTNP) subjects

Retrovirology

Volumn 6, Issue , 2009, Pages

  Canducci, Filippo ^a   Marinozzi, Maria Chiara ^a   Sampaolo, Michela ^a   Berrè, Stefano ^a   Bagnarelli, Patrizia ^b   Degano, Massimo ^c   Gallotta, Giulia ^a   Mazzi, Benedetta ^c   Lemey, Philippe ^d   Burioni, Roberto ^a   Clementi, Massimo ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; EPITOPE; GENOMIC RNA; GLYCOPROTEIN GP 120; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; VIRUS ENVELOPE PROTEIN; HLA B ANTIGEN;

ANTIGEN BINDING; ARTICLE; BINDING SITE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; DISEASE COURSE; EVOLUTIONARY RATE; GENE SEQUENCE; GLYCOSYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MOLECULAR CLONING; MUTATION RATE; NUCLEOTIDE SEQUENCE; PHYLOGENY; PROTEIN TARGETING; RNA SEQUENCE; SEQUENCE ANALYSIS; TREATMENT PLANNING; UNINDEXED SEQUENCE; VIRUS REPLICATION; AMINO ACID SEQUENCE; CHEMICAL STRUCTURE; CHEMISTRY; GENETIC SELECTION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MOLECULAR EVOLUTION; MOLECULAR GENETICS; MUTATION; PROTEIN BINDING; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

AMINO ACID SEQUENCE; ANTIGENS, CD4; BINDING SITES; CODON; DISEASE PROGRESSION; EVOLUTION, MOLECULAR; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HIV-1; HLA-B ANTIGENS; HUMANS; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; MUTATION; PROTEIN BINDING; SELECTION (GENETICS);

EID: 60849133898     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-6-4     Document Type: Article

References (65)

1. Richman DD Little SJ Smith DM Wrin T Petropoulos C Wong JK HIV Evolution and Escape Trans Am Clin Climatol Assoc 2004, 115:289-303 2263778 17060974
2. Frost SD Wrin T Smith DM Kosakovsky Pond SL Liu Y Paxinos E Chappey C Galovich J Beauchaine J Petropoulos CJ et al Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection Proc Natl Acad Sci USA 2005, 102(51):18514-18519 1310509 16339909 10.1073/pnas.0504658102
3. Clementi M Canducci F Bagnarelli P Menzo S Intra-host evolution of human immunodeficiency virus type 1 and viral fitness New Microbiol 2004, 27(2 Suppl 1):41-44 15646063
4. Quinones-Mateu ME Ball SC Marozsan AJ Torre VS Albright JL Vanham G van Der Groen G Colebunders RL Arts EJ A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression J Virol 2000, 74(19):9222-9233 102121 10982369 10.1128/JVI.74.19.9222-9233.2000
5. Arts EJ Quinones-Mateu ME Sorting out the complexities of HIV-1 fitness Aids 2003, 17(5):780-781 10.1097/00002030-200303280-00026 12646811
6. Rangel HR Weber J Chakraborty B Gutierrez A Marotta ML Mirza M Kiser P Martinez MA Este JA Quinones-Mateu ME Role of the human immunodeficiency virus type 1 envelope gene in viral fitness J Virol 2003, 77(16):9069-9073 167250 12885922 10.1128/JVI.77.16.9069-9073.2003
7. Bagnarelli P Vecchi M Burighel N Bellanova D Menzo S Clementi M De Rossi A Genotypic and phenotypic correlates of the HIV Type 1 env gene evolution in infected children with discordant response to antiretroviral therapy AIDS Res Hum Retroviruses 2004, 20(12):1306-1313 10.1089/aid.2004.20.1306 15650423
8. Menzo S Sampaolesi R Vicenzi E Santagostino E Liuzzi G Chirianni A Piazza M Cohen OJ Bagnarelli P Clementi M Rare mutations in a domain crucial for V3-loop structure prevail in replicating HIV from long-term non-progressors Aids 1998, 12(9):985-997 10.1097/ 00002030-199809000-00004 9662194
9. Frost SD Liu Y Pond SL Chappey C Wrin T Petropoulos CJ Little SJ Richman DD Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B J Virol 2005, 79(10):6523-6527 1091710 15858036 10.1128/JVI.79.10.6523-6527.2005
10. Riddle TM Shire NJ Sherman MS Franco KF Sheppard HW Nelson JA Sequential turnover of human immunodeficiency virus type 1 env throughout the course of infection J Virol 2006, 80(21):10591-10599 1641766 16956948 10.1128/JVI.00644-06
11. Srivastava IK Ulmer JB Barnett SW Role of neutralizing antibodies in protective immunity against HIV Hum Vaccin 2005, 1(2):45-60 17038830
12. Moore PL Crooks ET Porter L Zhu P Cayanan CS Grise H Corcoran P Zwick MB Franti M Morris L et al Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1 J Virol 2006, 80(5):2515-2528 1395414 16474158 10.1128/JVI.80.5.2515-2528.2006
13. Lee WR Syu WJ Du B Matsuda M Tan S Wolf A Essex M Lee TH Nonrandom distribution of gp120 N-linked glycosylation sites important for infectivity of human immunodeficiency virus type 1 Proc Natl Acad Sci USA 1992, 89(6):2213-2217 48627 1549584 10.1073/pnas.89.6.2213
14. Wei X Decker JM Wang S Hui H Kappes JC Wu X Salazar-Gonzalez JF Salazar MG Kilby JM Saag MS et al Antibody neutralization and escape by HIV-1 Nature 2003, 422(6929):307-312 10.1038/nature01470 12646921
15. Balzarini J Targeting the glycans of gp120: A novel approach aimed at the Achilles heel of HIV Lancet Infect Dis 2005, 5(11):726-731 10.1016/ S1473-3099(05)70271-1 16253890
16. Poon AF Lewis FI Pond SL Frost SD Evolutionary interactions between N-linked glycosylation sites in the HIV-1 envelope PLoS Comput Biol 2007, 3(1):e11 1779302 17238283 10.1371/journal.pcbi.0030011
17. Burton DR Desrosiers RC Doms RW Koff WC Kwong PD Moore JP Nabel GJ Sodroski J Wilson IA Wyatt RT HIV vaccine design and the neutralizing antibody problem Nat Immunol 2004, 5(3):233-236 10.1038/ni0304-233 14985706
18. Zolla-Pazner S Identifying epitopes of HIV-1 that induce protective antibodies Nat Rev Immunol 2004, 4(3):199-210 10.1038/nri1307 15039757
19. Braibant M Brunet S Costagliola D Rouzioux C Agut H Katinger H Autran B Barin F Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: Prevalence and association with neutralizing activity Aids 2006, 20(15):1923-1930 10.1097/ 01.aids.0000247113.43714.5e 16988513
20. Eggink D Melchers M Sanders RW et al Antibodies to HIV-1: Aiming at the right target Trends Microbiol 2007, 15(7):291-294 10.1016/ j.tim.2007.05.006 17566740
21. Dhillon AK Donners H Pantophlet R Johnson WE Decker JM Shaw GM Lee FH Richman DD Doms RW Vanham G Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors J Virol 2007, 81(12):6548-6562 1900098 17409160 10.1128/JVI.02749-06
22. Li Y Migueles SA Welcher B Svehla K Phogat A Louder MK Wu X Shaw GM Connors M Wyatt RT et al Broad HIV-1 neutralization mediated by CD4-binding site antibodies Nat Med 2007, 13(9):1032-1034 2584972 17721546 10.1038/nm1624
23. Moore PL Gray ES Choge IA Ranchobe N Mlisana K Abdool Karim SS Williamson C Morris L The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection J Virol 2008, 82(4):1860-1869 2258729 18057243 10.1128/ JVI.02187-07
24. Kupfer B Sing T Schuffler P Hall R Kurz R McKeown A Schneweis KE Eberl W Oldenburg J Brackmann HH et al Fifteen years of env C2V3C3 evolution in six individuals infected clonally with human immunodeficiency virus type 1 J Med Virol 2007, 79(11):1629-1639 10.1002/jmv.20976 17854039
25. Bunnik EM Pisas L van Nuenen AC Schuitemaker H Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection J Virol 2008, 82(16):7932-7941 2519599 18524815 10.1128/JVI.00757-08
26. Joos B Fischer M Schweizer A Kuster H Boni J Wong JK Weber R Trkola A Gunthard HF Positive in vivo selection of the HIV-1 envelope protein gp120 occurs at surface-exposed regions J Infect Dis 2007, 196(2):313-320 10.1086/518935 17570120
27. Choisy M Woelk CH Guegan JF Robertson DL Comparative study of adaptive molecular evolution in different human immunodeficiency virus groups and subtypes J Virol 2004, 78(4):1962-1970 369455 14747561 10.1128/ JVI.78.4.1962-1970.2004
28. Burton DR Stanfield RL Wilson IA et al Antibody vs. HIV in a clash of evolutionary titans Proc Natl Acad Sci USA 2005, 102(42):14943-14948 1257708 16219699 10.1073/pnas.0505126102
29. Gaschen B Taylor J Yusim K Foley B Gao F Lang D Novitsky V Haynes B Hahn BH Bhattacharya T Diversity considerations in HIV-1 vaccine selection Science 2002, 296(5577):2354-2360 10.1126/science.1070441 12089434
30. Scanlan CN Offer J Zitzmann N Dwek RA Exploiting the defensive sugars of HIV-1 for drug and vaccine design Nature 2007, 446(7139):1038-1045 10.1038/nature05818 17460665
31. Leal E Janini M Diaz RS Selective pressures of human immunodeficiency virus type 1 (HIV-1) during pediatric infection Infect Genet Evol 2007, 7(6):694-707 10.1016/j.meegid.2007.07.008 17719854
32. de Oliveira T Salemi M Gordon M Vandamme AM van Rensburg EJ Engelbrecht S Coovadia HM Cassol S Mapping sites of positive selection and amino acid diversification in the HIV genome: An alternative approach to vaccine design? Genetics 2004, 167(3):1047-1058 1470929 15280222 10.1534/ genetics.103.018135
33. Pybus OG Rambaut A Belshaw R Freckleton RP Drummond AJ Holmes EC Phylogenetic evidence for deleterious mutation load in RNA viruses and its contribution to viral evolution Mol Biol Evol 2007, 24(3):845-852 10.1093/molbev/msm001 17218639
34. Zhou T Xu L Dey B Hessell AJ Van Ryk D Xiang SH Yang X Zhang MY Zwick MB Arthos J et al Structural definition of a conserved neutralization epitope on HIV-1 gp120 Nature 2007, 445(7129):732-737 2584968 17301785 10.1038/nature05580
35. Salemi M Burkhardt BR Gray RR Ghaffari G Sleasman JW Goodenow MM Phylodynamics of HIV-1 in Lymphoid and Non-Lymphoid Tissues Reveals a Central Role for the Thymus in Emergence of CXCR4-Using Quasispecies PLoS ONE 2007, 2(9):e950 1978532 17895991 10.1371/journal.pone.0000950
36. Pond SL Frost SD Grossman Z Gravenor MB Richman DD Brown AJ Adaptation to different human populations by HIV-1 revealed by codon-based analyses PLoS Comput Biol 2006, 2(6):e62 1480537 16789820 10.1371/ journal.pcbi.0020062
37. Yamaguchi-Kabata Y Gojobori T Reevaluation of amino acid variability of the human immunodeficiency virus type 1 gp120 envelope glycoprotein and prediction of new discontinuous epitopes J Virol 2000, 74(9):4335-4350 111951 10756049 10.1128/JVI.74.9.4335-4350.2000
38. Sheridan I Pybus OG Holmes EC Klenerman P High-resolution phylogenetic analysis of hepatitis C virus adaptation and its relationship to disease progression J Virol 2004, 78(7):3447-3454 371055 15016867 10.1128/ JVI.78.7.3447-3454.2004
39. Bazykin GA Dushoff J Levin SA Kondrashov AS Bursts of nonsynonymous substitutions in HIV-1 evolution reveal instances of positive selection at conservative protein sites Proc Natl Acad Sci USA 2006, 103(51):19396-19401 1698441 17164328 10.1073/pnas.0609484103
40. Lemey P Rambaut A Pybus OG HIV evolutionary dynamics within and among hosts AIDS Rev 2006, 8(3):125-140 17078483
41. Lemey P Kosakovsky Pond SL Drummond AJ Pybus OG Shapiro B Barroso H Taveira N Rambaut A Synonymous substitution rates predict HIV disease progression as a result of underlying replication dynamics PLoS Comput Biol 2007, 3(2):e29 1797821 17305421 10.1371/journal.pcbi.0030029
42. McMichael A Klenerman P HIV/AIDS. HLA leaves its footprints on HIV Science 2002, 296(5572):1410-1411 10.1126/science.1072492 12029119
43. Carrington M O'Brien SJ The influence of HLA genotype on AIDS Annu Rev Med 2003, 54:535-551 10.1146/annurev.med.54.101601.152346 12525683
44. Peyerl FW Bazick HS Newberg MH Barouch DH Sodroski J Letvin NL Fitness costs limit viral escape from cytotoxic T lymphocytes at a structurally constrained epitope J Virol 2004, 78(24):13901-13910 533946 15564498 10.1128/JVI.78.24.13901-13910.2004
45. Fellay J Shianna KV Ge D Colombo S Ledergerber B Weale M Zhang K Gumbs C Castagna A Cossarizza A et al A whole-genome association study of major determinants for host control of HIV-1 Science 2007, 317(5840):944-947 1991296 17641165 10.1126/science.1143767
46. Moore CB John M James IR Christiansen FT Witt CS Mallal SA Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level Science 2002, 296(5572):1439-1443 10.1126/science.1069660 12029127
47. Mallal S Nolan D Witt C Masel G Martin AM Moore C Sayer D Castley A Mamotte C Maxwell D et al Association between presence of HLA-B* HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir Lancet 5701, 359(9308):727-732 10.1016/ S0140-6736(02)07873-X
48. Bailey JR Zhang H Wegweiser BW Yang HC Herrera L Ahonkhai A Williams TM Siliciano RF Blankson JN Evolution of HIV-1 in an HLA-B*57-positive patient during virologic escape J Infect Dis 2007, 196(1):50-55 10.1086/518515 17538883
49. Dong T Stewart-Jones G Chen N Easterbrook P Xu X Papagno L Appay V Weekes M Conlon C Spina C et al HIV-specific cytotoxic T cells from long-term survivors select a unique T cell receptor J Exp Med 2004, 200(12):1547-1557 2212004 15596521 10.1084/jem.20032044
50. Wang S Sun Y Zhai S Zhuang Y Zhao S Kang W Li X Huang D Yu XG Walker BD et al Identification of HLA-A11-restricted HIV-1-specific cytotoxic T-lymphocyte epitopes in China Curr HIV Res 2007, 5(1):119-128 10.2174/ 157016207779316404 17266563
51. Gnanakaran S Lang D Daniels M Bhattacharya T Derdeyn CA Korber B Clade-specific differences between human immunodeficiency virus type 1 clades B and C: Diversity and correlations in C3-V4 regions of gp120 J Virol 2007, 81(9):4886-4891 1900169 17166900 10.1128/JVI.01954-06
52. Pinter A Roles of HIV-1 Env variable regions in viral neutralization and vaccine development Curr HIV Res 2007, 5(6):542-553 10.2174/ 157016207782418470 18045110
53. Pantophlet R Burton DR GP120: Target for neutralizing HIV-1 antibodies Annu Rev Immunol 2006, 24:739-769 10.1146/ annurev.immunol.24.021605.090557 16551265
54. Vaine M Wang S Crooks ET Jiang P Montefiori DC Binley J Lu S Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination J Virol 2008, 82(15):7369-7378 2493346 18495775 10.1128/JVI.00562-08
55. Karlsson Hedestam GB Fouchier RA Phogat S Burton DR Sodroski J Wyatt RT The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus Nat Rev Microbiol 2008, 6(2):143-155 10.1038/nrmicro1819 18197170
56. McKnight A Aasa-Chapman MM Clade specific neutralising vaccines for HIV: an appropriate target? Curr HIV Res 2007, 5(6):554-560 10.2174/ 157016207782418524 18045111
57. Dacheux L Moreau A Ataman-Onal Y Biron F Verrier B Barin F Evolutionary dynamics of the glycan shield of the human immunodeficiency virus envelope during natural infection and implications for exposure of the 2G12 epitope J Virol 2004, 78(22):12625-12637 525068 15507649 10.1128/ JVI.78.22.12625-12637.2004
58. Mehandru S Vcelar B Wrin T Stiegler G Joos B Mohri H Boden D Galovich J Tenner-Racz K Racz P et al Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection J Virol 2007, 81(20):11016-11031 2045579 17686878 10.1128/JVI.01340-07
59. Manrique A Rusert P Joos B Fischer M Kuster H Leemann C Niederost B Weber R Stiegler G Katinger H et al In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10 J Virol 2007, 81(16):8793-8808 1951363 17567707 10.1128/JVI.00598-07
60. Scanlan CN Pantophlet R Wormald MR Ollmann Saphire E Stanfield R Wilson IA Katinger H Dwek RA Rudd PM Burton DR The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1>2 mannose residues on the outer face of gp120 J Virol 2002, 76(14):7306-7321 136327 12072529 10.1128/ JVI.76.14.7306-7321.2002
61. Trkola A Kuster H Rusert P Joos B Fischer M Leemann C Manrique A Huber M Rehr M Oxenius A et al Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies Nat Med 2005, 11(6):615-622 10.1038/nm1244 15880120
62. Nakowitsch S Quendler H Fekete H Kunert R Katinger H Stiegler G HIV-1 mutants escaping neutralization by the human antibodies 2F5, 2G12, and 4E10: In vitro experiments versus clinical studies Aids 2005, 19(17):1957-1966 10.1097/01.aids.0000189856.13817.76 16260901
63. Yang Z Maximum likelihood analysis of adaptive evolution in HIV-1 gp120 env gene Pac Symp Biocomput 2001:226-237 11262943
64. Yang Z Wong WS Nielsen R Bayes empirical bayes inference of amino acid sites under positive selection Mol Biol Evol 2005, 22(4):1107-1118 10.1093/molbev/msi097 15689528
65. Huang CC Tang M Zhang MY Majeed S Montabana E Stanfield RL Dimitrov DS Korber B Sodroski J Wilson IA et al. Structure of a V3-containing HIV-1 gp120 core Science 2005, 310(5750):1025-1028 2408531 16284180 10.1126/ science.1118398